Early-demographic dividend vs Kazakhstan: Immunization, Hib3
Immunization, Hib3 over time
- Early-demographic dividend
- Kazakhstan
How they compare
Kazakhstan currently reports 98.0% against 86.1% in Early-demographic dividend, a difference of 11.9%.
That makes Kazakhstan's figure about 1.1 times Early-demographic dividend's.
The two have swapped places 2 times across 17 shared years of data; in 2008 it was Kazakhstan ahead.
Early-demographic dividend ranks 17th and Kazakhstan ranks 20th of 43 groups.
Kazakhstan has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Early-demographic dividend | Kazakhstan | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 26.2% | 73.0% | 46.8% | Kazakhstan |
| 2010s | 61.9% | 95.6% | 33.7% | Kazakhstan |
| 2020s | 84.4% | 95.8% | 11.4% | Kazakhstan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher immunization, hib3, Early-demographic dividend or Kazakhstan?
- Kazakhstan, at 98.0% against 86.1% in Early-demographic dividend as of 2024.
- What is the difference in immunization, hib3 between Early-demographic dividend and Kazakhstan?
- 11.9%, with Kazakhstan ahead.
- How many years of comparable data are there for Early-demographic dividend and Kazakhstan?
- 17 years are reported by both, from 2008 to 2024.
- How do Early-demographic dividend and Kazakhstan rank globally for immunization, hib3?
- Early-demographic dividend ranks 17th and Kazakhstan ranks 20th of 43 groups.
- Where does this data come from?
- WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/), published as Immunization, Hib3 (% of children ages 12-23 months). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Child immunization, Hib3, measures the percentage of children ages 12-23 months who received Hib3 vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against Hib3 after receiving three doses of Haemophilus influenzae type b vaccine.